<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923676</url>
  </required_header>
  <id_info>
    <org_study_id>DGMM/03/2007</org_study_id>
    <nct_id>NCT00923676</nct_id>
  </id_info>
  <brief_title>Treatment of Hyperlipidemia and Sexual Dysfunction</brief_title>
  <official_title>Effect of Fenofibrate and Rosuvastatin on Sexual Dysfunction in Hyperlipidemic Patients. A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperlipidemias are frequently associated with and are considered an important cause of
      erectile dysfunction in men. This association has been attributed to the impairment of blood
      flow through endothelium-dependent relaxation in smooth muscle cells of corpus cavernosum.
      Basic science and human research suggest that the vascular pathophysiology of male and female
      sexual dysfunction may be similar, as the first phase of the female sexual response is
      mediated by a combination of vasocongestive and neuro-muscular event which include increased
      clitoral length and diameter, as well as increased vaginal lubrication, wall engorgement and
      luminal diameter. The investigators have shown that women with hyperlipidemia had a higher
      prevalence of sexual dysfunction as compared with age-matched women without hyperlipidemia.

      The aim of this study was to asses the effect of anti-hyperlipidemic drugs (fenofibrate and
      rosuvastatin, single or in combination) on validated indices of sexual function in
      hyperlipidemic men and women with sexual dysfunction at baseline.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International index of erectile dysfunction (IIEF) in men and Female sexual function index (FSFI) in women</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lipids, inflammatory markers</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fenofibrate + rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fenofibrate pills + rosuvastatin pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>pill 145 mg, 145 mg/day, for 12 months</description>
    <arm_group_label>Fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>pills of 10 mg, 10 mg/day, 12 months</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate + rosuvastatin</intervention_name>
    <description>fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months</description>
    <arm_group_label>fenofibrate + rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low-density lipoprotein (LDL)-cholesterol levels &gt; 160 mg/dL, high-density lipoprotein
             (HDL)-cholesterol levels &lt; 50 mg/dL (for women) and &lt; 40 mg/dl (for men), or
             triglyceride levels &gt; 150 mg/dL.

          -  Stable heterosexual partner relationship for the preceding 6 months.

        Exclusion Criteria:

          -  Pregnancy or less than 8 weeks postpartum.

          -  Diabetes mellitus (fasting glucose &gt; 126 mg/dl.

          -  Uremia.

          -  Multiple sclerosis.

          -  Chronic alcoholism (intake of â‰¥ 500g/wk).

          -  Cancer.

          -  Psychiatric problems.

          -  Symptomatic cardiovascular disease.

          -  Gynecological surgery.

          -  Pelvic trauma.

          -  Polycystic ovarian syndrome.

          -  Abnormal thyroid function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dario Giugliano, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Geriatrics and Metabolic Diseases, Second University of Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Geriatrics and Metabolic Diseases</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Esposito K, Ciotola M, Maiorino MI, Giugliano F, Autorino R, De Sio M, Cozzolino D, Saccomanno F, Giugliano D. Hyperlipidemia and sexual function in premenopausal women. J Sex Med. 2009 Jun;6(6):1696-1703. doi: 10.1111/j.1743-6109.2009.01284.x. Epub 2009 Apr 23.</citation>
    <PMID>19453904</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Dario Giugliano</investigator_full_name>
    <investigator_title>Prof of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>LDL-cholesterol</keyword>
  <keyword>HDL-cholesterol</keyword>
  <keyword>triglycerides</keyword>
  <keyword>IIEF</keyword>
  <keyword>FSFI</keyword>
  <keyword>Male and female sexual dysfunctions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

